Business
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":409,"url":"https://media.zenfs.com/en/business-wire.com/6f4fb020fe518bebbee1a057829a94c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EYlT3tsvKhJZtlkBpPUy4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTgxODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6f4fb020fe518bebbee1a057829a94c8","width":480,"height":409}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ultra long-acting pipeline","length":224,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"12-month data to be presented for investigational lotivibart (N6LS) + cabotegravir long-acting, evaluating feasibility of ultra long-acting dosing intervals","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Clinical data and real-world evidence from ViiV’s innovative portfolio include insights for established INSTI-based long-acting Cabenuva (cabotegravir + rilpivirine LA) and 2-drug regimen Dovato (dolutegravir/lamivudine)","length":220,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":600,"olType":false},{"type":"text","content":"LONDON, February 17, 2026--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.","length":415,"tagName":"p"},{"type":"text","content":"Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: "We are making major advances towards new ultra long‑acting regimens that build on ViiV’s legacy of integrase inhibitors, including pipeline assets such as VH184 that have the potential to extend dosing intervals to four months or longer – beyond what is available today for HIV treatment. Listening to the needs of the HIV community shapes our research and development, and the breadth ...